| Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
| Mylan Pharms. Inc. v. Shire Labs., Inc., IPR2017-00011 (PTAB) |
Oct. 4, 2016 |
N/A |
Adderall XR® (amphetamine aspartate / amphetamine sulfate / dextroamphetamine saccharate / dextroamphetamine sulfate extended-release capsules) |
RE41,148 |
| Amgen Inc. v. Ajanta Pharma Ltd., 16-0899 (D. Del.) |
Oct. 5, 2016 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet hydrochloride tablets) |
9,375,405 |
| Amgen Inc. v. Dr. Reddy’s Labs., Ltd., 16-0900 (D. Del.) |
Oct. 5, 2016 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet hydrochloride tablets) |
9,375,405 |
| UCB, Inc. v. Zydus Pharms. (USA) Inc., 16-0903 (D. Del.) |
Oct. 6, 2016 |
Hon. Leonard P. Stark |
Vimpat® (lacosamide for injection) |
RE38,551 |
| Astellas Pharma Inc. v. Actavis Elizabeth LLC, 16-0905 (D. Del.) |
Oct. 6, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
6,346,532, 7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Alcon Research, Ltd. v. Apotex Inc., 16-0906 (D. Del.) |
Oct. 6, 2016 |
Hon. Sue L. Robinson |
Pazeo® (olopatadine hydrochloride ophthalmic solution) |
8,791,154 |
| Astellas Pharma Inc. v. Lupin Ltd., 16-0908 (D. Del.) |
Oct. 7, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Alza Corp. v. Amneal Pharms. of New York, LLC, 16-0914 (D. Del.) |
Oct. 7, 2016 |
Hon. Richard G. Andrews |
Concerta® (methylphenidate hydrochloride tablets) |
8,163,798, 9,144,549 |
| Forest Labs., LLC v. Amerigen Pharms., Inc., 16-0917 (D. Del.) |
Oct. 7, 2016 |
Hon. Leonard P. Stark |
Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009, 8,058,291, 8,168,209, 8,173,708, 8,283,379, 8,293,794, 8,329,752, 8,338,485, 8,338,486, 8,362,085, 8,580,858, 8,598,233 |
| Alcon Pharms. Ltd. v. Dr. Reddy’s Labs., Inc., 16-6775 (D.N.J.) |
Oct. 7, 2016 |
Hon. Peter G. Sheridan |
Ciprodex® (ciprofloxacin / dexamethasone otic suspension) |
9,402,805 |
| Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2017-00041 (PTAB) |
Oct. 7, 2016 |
N/A |
Xarelto® (rivaroxaban tablets) |
7,157,456 |
| Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2017-00042 (PTAB) |
Oct. 7, 2016 |
N/A |
Xarelto® (rivaroxaban tablets) |
7,585,860 |
| Mylan Pharms. Inc. v. Bayer Intellectual Property GmbH, IPR2017-00043 (PTAB) |
Oct. 7, 2016 |
N/A |
Xarelto® (rivaroxaban tablets) |
7,592,339 |
| Astellas Pharma Inc. v. Zydus Pharms. (USA), Inc., 16-0924 (D. Del.) |
Oct. 11, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Amgen Inc. v. Amneal Pharms. LLC, 16-0925 (D. Del.) |
Oct. 11, 2016 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet hydrochloride tablets) |
9,375,405 |
| Amgen Inc. v. Apotex Inc., 16-0926 (D. Del.) |
Oct. 11, 2016 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet hydrochloride tablets) |
9,375,405 |
| Amgen Inc. v. Breckenridge Pharm. Inc., 16-0927 (D. Del.) |
Oct. 11, 2016 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet hydrochloride tablets) |
9,375,405 |
| Amgen Inc. v. Hetero USA Inc., 16-0928 (D. Del.) |
Oct. 11, 2016 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet hydrochloride tablets) |
9,375,405 |
| Astellas Pharma Inc. v. Windlas Healthcare, Pvt. Ltd., 16-0930 (D. Del.) |
Oct. 12, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Astellas Pharma Inc. v. Aurobindo Pharma Ltd., 16-0942 (D. Del.) |
Oct. 13, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Astellas Pharma Inc. v. Prinston Pharm. Inc., 16-0943 (D. Del.) |
Oct. 13, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Mallinckrodt Hospital Products IP Ltd. v. Praxair Distribution, Inc., 16-0944 (D. Del.) |
Oct. 13, 2016 |
Hon. Gregory M. Sleet |
Inomax® (nitric oxide for inhalation) |
9,408,993 |
| Astellas Pharma Inc. v. Sandoz Inc., 16-0952 (D. Del.) |
Oct. 14, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| AstraZeneca AB v. Glenmark Pharms. Ltd., 16-7330 (D.N.J.) |
Oct. 14, 2016 |
Hon. Mary L. Cooper |
Nexium® 24HR (esomeprazole magnesium delayed-release capsules) |
6,369,085, 7,411,070, 8,466,175 |
| Otsuka Pharm. Co., Ltd. v. Stason Indus. Corp., 16-7346 (D.N.J.) |
Oct. 14, 2016 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
9,359,302 |
| Astellas Pharma Inc. v. Sawai Pharm. Co., Ltd., 16-0954 (D. Del.) |
Oct. 17, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
6,346,532, 7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Celgene Corp. v. Dr. Reddy’s Labs., Ltd., 16-7704 (D.N.J.) |
Oct. 20, 2016 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
7,465,800, 7,855,217, 7,968,569, 8,530,498, 8,648,095, 9,101,621, 9,101,622 |
| Astellas Pharma Inc. v. Apotex Inc., 16-0976 (D. Del.) |
Oct. 21, 2016 |
Hon. Sue L. Robinson |
Myrbetriq® (mirabegron extended-release tablets) |
7,342,117, 7,982,049, 8,835,474, RE44,872 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 16-7705 (D.N.J.) |
Oct. 21, 2016 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
9,359,302 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 16-7721 (D.N.J.) |
Oct. 21, 2016 |
Hon. Jose L. Linares |
Narcan® (naloxone hydrochloride nasal spray) |
9,211,253 |
| Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., 16-0987 (D. Del.) |
Oct. 24, 2016 |
Hon. Sue L. Robinson |
Colcrys® (colchicine tablets) |
7,906,519, 7,935,731, 8,093,298, 7,964,648, 8,093,297, 7,619,004, 7,601,758, 7,820,681, 7,915,269, 7,964,647, 7,981,938, 8,093,296, 8,097,655, 8,415,395, 8,415,396, 8,440,721, 8,440,722 |
| Onyx Therapeutics, Inc. v. Cipla Ltd., 16-0988 (D. Del.) |
Oct. 24, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
| Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., 16-0202 (N.D.W.V.) |
Oct. 25, 2016 |
Hon. Irene M. Keeley |
Colcrys® (colchicine tablets) |
7,906,519, 7,935,731, 8,093,298, 7,964,648, 8,093,297, 7,619,004, 7,601,758, 7,820,681, 7,915,269, 7,964,647, 7,981,938, 8,093,296, 8,097,655, 8,415,395, 8,415,396, 8,440,721, 8,440,722 |
| Millennium Pharms., Inc. v. Hospira, Inc., 16-0998 (D. Del.) |
Oct. 26, 2016 |
Hon. Gregory M. Sleet |
Velcade® (bortezomib for injection) |
6,713,446 |
| Onyx Therapeutics, Inc. v. MSN Pharms., Inc., 16-0999 (D. Del.) |
Oct. 26, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,737,112 |
| Onyx Therapeutics, Inc. v. Sagent Pharms., Inc., 16-1000 (D. Del.) |
Oct. 26, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
| Eli Lilly and Co. v. Cipla Ltd., 16-2911 (S.D. Ind.) |
Oct. 26, 2016 |
Hon. Richard L. Young |
Axiron® (testosterone metered transdermal solution) |
8,435,944, 8,993,520, 9,180,194 |
| Onyx Therapeutics, Inc. v. Breckenridge Pharm., Inc., 16-1001 (D. Del.) |
Oct. 27, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
| Galderma Labs., L.P. v. Sun Pharm. Indus. Ltd., 16-1003 (D. Del.) |
Oct. 27, 2016 |
Hon. Leonard P. Stark |
Oracea® (doxycycline tablets) |
7,211,267, 7,232,572, 8,603,506, 7,749,532, 8,206,740, 8,394,405, 8,394,406, 8,470,364, 8,709,478, 9,241,946 |
| Eli Lilly and Co. v. Cipla Ltd., 16-1005 (D. Del.) |
Oct. 28, 2016 |
Hon. Sue L. Robinson |
Axiron® (testosterone metered transdermal solution) |
8,435,944, 8,993,520, 9,180,194 |
| Eli Lilly and Co. v. Accord Healthcare, Inc., 16-1352 (E.D. Va.) |
Oct. 28, 2016 |
Hon. Anthony J. Trenga |
Cialis® (tadalafil tablets) |
6,943,166 |
| Indivior Inc. v. Actavis Labs. UT, Inc., 16-1009 (D. Del.) |
Oct. 31, 2016 |
Hon. Richard G. Andrews |
Suboxone® (buprenorphine / naloxone sublingual film) |
8,475,832, 8,017,150, 8,603,514 |
| Otsuka Pharm. Co., Ltd. v. Indoco Remedies Ltd., 16-8085 (D.N.J.) |
Oct. 31, 2016 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
9,359,302, 9,387,182 |
| Amarin Pharma, Inc. v. Roxane Labs., Inc., 16-2525 (D. Nev.) |
Oct. 31, 2016 |
Hon. Miranda M. Du |
Vascepa® (icosapent ethyl capsules) |
8,293,728, 8,318,715, 8,357,677, 8,367,652, 8,377,920, 8,399,446, 8,415,335, 8,426,399, 8,431,560, 8,440,650, 8,518,929, 8,524,698, 8,546,372, 8,617,594 |
| Onyx Therapeutics, Inc. v. Dr. Reddy’s Labs., Inc., 16-1011 (D. Del.) |
Nov. 1, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,737,112 |
| Onyx Therapeutics, Inc. v. Fresenius Kabi USA, LLC, 16-1012 (D. Del.) |
Nov. 1, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042, 7,232,818, 7,491,704, 7,737,112, 8,129,346, 8,207,125, 8,207,126, 8,207,127, 8,207,297 |
| Onyx Therapeutics, Inc. v. Qilu Pharma, Inc., 16-1013 (D. Del.) |
Nov. 1, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,737,112 |
| Eli Lilly and Co. v. Fresenius Kabi USA, LLC, 16-2960 (S.D. Ind.) |
Nov. 1, 2016 |
Hon. Tanya Walton Pratt |
Alimta® (pemetrexed disodium for injection) |
7,772,209 |
| Acrux DDS Pty Ltd. v. Kaken Pharm. Co., Ltd., IPR2017-00190 (PTAB) |
Nov. 2, 2016 |
N/A |
Jublia® (efinaconazole topical solution) |
7,214,506 |
| Mylan Pharms. Inc. v. Yeda Research & Development Co., Ltd., IPR2017-00195 (PTAB) |
Nov. 2, 2016 |
N/A |
Copaxone® (glatiramer acetate injection) |
9,155,776 |
| UCB, Inc. v. Zydus Worldwide DMCC, 16-1023 (D. Del.) |
Nov. 3, 2016 |
Hon. Sue L. Robinson |
Neupro® (rotigotine transdermal system) |
8,246,979, 8,246,980, 8,617,591, 6,884,434 |
| Medicis Pharm. Corp. v. Dr. Reddy’s Labs., Ltd., 16-8282 (D.N.J.) |
Nov. 4, 2016 |
Hon. Brian R. Martinotti |
Solodyn® (minocycline hydrochloride extended-release tablets) |
5,908,838, 7,790,705, 7,919,483, 8,252,776, 8,268,804, 8,722,650 |
| Otsuka Pharm. Co., Ltd. v. Zhejiang Huahai Pharm. Co., Ltd., 16-8284 (D.N.J.) |
Nov. 4, 2016 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
9,359,302, 9,387,182 |
| Amarin Pharma, Inc. v. Dr. Reddy’s Labs., Inc., 16-2562 (D. Nev.) |
Nov. 4, 2016 |
Hon. Robert C. Jones |
Vascepa® (icosapent ethyl capsules) |
8,293,728, 8,318,715, 8,357,677, 8,367,652, 8,377,920, 8,399,446, 8,415,335, 8,426,399, 8,431,560, 8,440,650, 8,518,929, 8,524,698, 8,546,372, 8,617,594 |
| Mylan Technologies, Inc. v. Monosol Rx, LLC, IPR2017-00200 (PTAB) |
Nov. 4, 2016 |
N/A |
Suboxone® (buprenorphine / naloxone sublingual film) |
8,603,514 |
| Mylan Pharms. Inc. v. Qualicaps Co.Ltd, IPR2017-00203 (PTAB) |
Nov. 4, 2016 |
N/A |
Delzicol® (mesalamine delayed-release capsule) |
6,649,180 |
| Onyx Therapeutics, Inc. v. InnoPharma, Inc., 16-1036 (D. Del.) |
Nov. 8, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042, 7,737,112, 8,207,297 |
| Onyx Therapeutics, Inc. v. Apotex Inc., 16-1039 (D. Del.) |
Nov. 8, 2016 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,737,112 |
| Forest Labs., LLC v. Apotex Corp., 16-1045 (D. Del.) |
Nov. 10, 2016 |
Hon. Leonard P. Stark |
Namzaric® (memantine hydrochloride / donepezil hydrochloride extended-release capsules) |
8,039,009, 8,058,291, 8,338,485, 8,338,486, 8,580,858 |
| Alcon Research, Ltd. v. Akorn, Inc., 16-3092 (S.D. Ind.) |
Nov. 11, 2016 |
Hon. Jane Magnus-Stinson |
Pataday® (olopatadine hydrochloride ophthalmic solution) |
6,995,186, 7,402,609 |
| The Medicines Co. v. Akorn, Inc., 16-8546 (D.N.J.) |
Nov. 15, 2016 |
Hon. Peter G. Sheridan |
Angiomax® (bivaluirudin for injection) |
7,582,727, 7,598,343 |
| United Therapeutics Corp. v. Par Sterile Products, LLC, 16-8548 (D.N.J.) |
Nov. 16, 2016 |
Hon. Peter G. Sheridan |
Remodulin® (treprostinil sodium for injection) |
8,497,393, 9,199,908, 7,999,007, 8,653,137, 8,658,694 |
| United Therapeutics Corp. v. Par Sterile Products, LLC, 16-1066 (D. Del.) |
Nov. 17, 2016 |
Hon. Sue L. Robinson |
Remodulin® (treprostinil sodium for injection) |
8,497,393, 9,199,908, 7,999,007, 8,653,137, 8,658,694 |
| Apotex Inc. v. Alcon Research, Ltd., 16-3145 (S.D. Ind.) |
Nov. 17, 2016 |
Hon. William T. Lawrence |
Pataday® (olopatadine hydrochloride ophthalmic solution) |
6,995,186, 7,402,609 |
| Alkermes Pharma Ireland Ltd. v. Otsuka Pharm. Co., Ltd., IPR2017-00287 (PTAB) |
Nov. 17, 2016 |
N/A |
Abilify® (aripiprazole tablets) |
9,125,939 |
| Aptalis Pharma Canada ULC v. Par Pharm., Inc., 16-1069 (D. Del.) |
Nov. 18, 2016 |
Hon. Sue L. Robinson |
Pylera® (bismuth subcitrate potassium / metronidazole / tetracycline hydrochloride capsules) |
6,350,468 |
| Amarin Pharma, Inc. v. Teva Pharms. USA, Inc., 16-2658 (D. Nev.) |
Nov. 18, 2016 |
Hon. Miranda M. Du |
Vascepa® (icosapent ethyl capsules) |
8,293,728, 8,318,715, 8,357,677, 8,367,652, 8,377,920, 8,399,446, 8,415,335, 8,426,399, 8,431,560, 8,440,650, 8,518,929, 8,524,698, 8,546,372, 8,617,594 |
| Mylan Pharms. Inc. v. Icos Corp., IPR2017-00323 (PTAB) |
Nov. 22, 2016 |
N/A |
Cialis® (tadalafil tablets) |
6,943,166 |
| Merck, Sharp & Dohme Corp. v. Strides Pharma Inc., 16-8850 (D.N.J.) |
Nov. 29, 2016 |
Hon. Brian R. Martinotti |
Sustiva® (efavirenz tablets) |
6,639,071, 6,939,964, 6,673,372 |
| Forest Labs., LLC v. Teva Pharms. USA, Inc., 16-1114 (D. Del.) |
Nov. 30, 2016 |
Hon. Richard G. Andrews |
Linzess® (linaclotide capsules) |
7,304,036, 7,371,727, 7,704,947, 7,745,409, 8,080,526, 8,110,553, 8,748,573, 8,802,628, 8,933,030 |
| Eli Lilly and Co. v. Apotex, Inc., 16-0941 (E.D. Va.) |
Nov. 30, 2016 |
Hon. M. Hannah Lauck |
Cialis® (tadalafil tablets) |
6,943,166 |
| Mallinckrodt IP v. Mylan Labs. Ltd., 16-1115 (D. Del.) |
Dec. 1, 2016 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen for injection) |
6,028,222, 6,992,218 |
| Malinckrodt IP v. Innopharma Licensing LLC, 16-1116 (D. Del.) |
Dec. 1, 2016 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen for injection) |
9,399,012 |
| Astellas Pharma Inc. v. Actavis Labs. FL, Inc., 16-1120 (D. Del.) |
Dec. 2, 2016 |
Hon. Gregory M. Sleet |
Xtandi® (enzalutamide capsules) |
7,709,517, 8,183,274, 9,126,941 |
| Merck, Sharp & Dohme Corp. v. Aurobindo Pharma Ltd., 16-9033 (D.N.J.) |
Dec. 6, 2016 |
Hon. Brian R. Martinotti |
Sustiva® (efavirenz tablets) |
6,639,071, 6,939,964, 6,673,372 |
| Horizon Pharma, Inc. v. Dr. Reddy’s Labs. Inc., 16-9035 (D.N.J.) |
Dec. 6, 2016 |
Hon. Mary L. Cooper |
Vimovo® (naproxen / esomeprazole magnesium delayed-release tablets) |
9,393,208 |
| Valeant Pharms. Int’l, Inc. v. Actavis Labs. FL, Inc., 16-9038 (D.N.J.) |
Dec. 6, 2016 |
Hon. Stanley R. Chesler |
Relistor® (methylnaltrexone bromide tablets) |
8,420,663, 8,524,276, 8,956,651, 9,180,125, 9,314,461 |
| MonoSol Rx, LLC v. Icos Corp., IPR2017-00412 (PTAB) |
Dec. 6, 2016 |
N/A |
Cialis® (tadalafil tablets) |
6,943,166 |
| Orexo AB v. Actavis Elizabeth LLC, 16-1138 (D. Del.) |
Dec. 7, 2016 |
Hon. Sue L. Robinson |
Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) |
9,439,900 |
| Orexo AB v. Actavis Elizabeth LLC, 16-1139 (D. Del.) |
Dec. 7, 2016 |
Hon. Sue L. Robinson |
Zubsolv® (buprenorphine hydrochloride / naloxone hydrochloride dihydrate sublingual tablets) |
9,439,900 |
| Abraxis Bioscience, LLC v. Cipla Ltd., 16-9074 (D.N.J.) |
Dec. 7, 2016 |
Hon. John Michael Vazquez |
Abraxane® (paclitaxel protein-bound particles for injectable suspension) |
7,820,788, 7,923,536, 8,138,229, 8,853,260 |
| Astellas Pharma Inc. v. Apotex Inc., 16-1166 (D. Del.) |
Dec. 9, 2016 |
Hon. Gregory M. Sleet |
Xtandi® (enzalutamide capsules) |
7,709,517, 8,183,274, 9,126,941 |
| Astellas Pharma Inc. v. Zydus Pharms. (USA) Inc., 16-1167 (D. Del.) |
Dec. 9, 2016 |
Hon. Gregory M. Sleet |
Xtandi® (enzalutamide capsules) |
7,709,517, 8,183,274, 9,126,941 |
| Apicore US LLC v. Pfizer Inc., 16-1174 (D. Del.) |
Dec. 12, 2016 |
Hon. Sue L. Robinson |
Tikosyn® (dofetilide capsules) |
6,124,363 |
| Eli Lilly and Co. v. Ajanta Pharma, Ltd., 16-0714 (E.D. Va.) |
Dec. 13, 2016 |
Hon. Mark S. Davis |
Cialis® (tadalafil tablets) |
6,943,166 |
| Bayer Healthcare LLC v. Teva Pharms. USA, Inc., 16-1220 (D. Del.) |
Dec. 16, 2016 |
Hon. Leonard P. Stark |
Nexavar (sorafenib tosylate tablets) |
8,877,933 |
| Bayer Healthcare LLC v. Teva Pharms. USA, Inc., 16-1221 (D. Del.) |
Dec. 16, 2016 |
Hon. Leonard P. Stark |
Stivarga® (regorafenib tablets) |
7,351,834, 8,637,553, 8,680,124, 9,458,107 |
| Bayer Healthcare LLC v. Apotex, Inc., 16-1222 (D. Del.) |
Dec. 16, 2016 |
Hon. Leonard P. Stark |
Stivarga® (regorafenib tablets) |
8,637,553 |
| Millennium Pharms., Inc. v. MSN Labs. Private Ltd., 16-1255 (D. Del.) |
Dec. 19, 2016 |
Hon. Gregory M. Sleet |
Velcade® (bortezomib for injection) |
6,713,446, 6,958,319 |
| Teva Pharms. USA, Inc. v. Dr. Reddy’s Labs., Ltd., 16-1267 (D. Del.) |
Dec. 19, 2016 |
Hon. Gregory M. Sleet |
Copaxone® (glatiramer acetate injection) |
9,402,874 |
| Impax Labs., Inc. v. Actavis Labs. FL, Inc., 16-9416 (D.N.J.) |
Dec. 20, 2016 |
Hon. Stanley R. Chesler |
Rytary® (levodopa / carbidopa extended-release capsules) |
9,463,246 |
| Eli Lilly and Co. v. Hospira, Inc., 16-3460 (S.D. Ind.) |
Dec. 21, 2016 |
Hon. Sarah Evans Barker |
Alimta® (pemetrexed disodium for injection) |
7,772,209 |
| Sanofi-Aventis U.S. LLC v. Watson Labs., Inc., 16-1298 (D. Del.) |
Dec. 22, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Sanofi-Aventis U.S. LLC v. Aurobindo Pharma USA, Inc., 16-1299 (D. Del.) |
Dec. 22, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Sanofi-Aventis U.S. LLC v. Alvogen Pine Brook LLC, 16-1300 (D. Del.) |
Dec. 22, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Biodelivery Sciences Int’l, Inc. v. Teva Pharms. USA, Inc., 16-1303 (D. Del.) |
Dec. 22, 2016 |
Hon. Gregory M. Sleet |
Belbuca® (buprenorphine buccal film) |
7,579,019, 8,147,866 |
| Allergan, Inc. v. Deva Holding A.S., 16-1447 (E.D. Tex.) |
Dec. 22, 2016 |
Hon. Robert W. Schroeder, III |
Restasis® (cyclosporine ophthalmic emulsion) |
8,629,111, 8,633,162, 8,642,556, 8,648,048, 8,685,930, 9,248,191 |
| Wyeth LLC v. Alembic Pharms., Ltd., 16-1305 (D. Del.) |
Dec. 23, 2016 |
Hon. Richard G. Andrews |
Bosulif® (bosutinib tablets) |
7,417,148, 7,767,678 |
| Rhodes Pharms. L.P. v. Indivior Inc., 16-1308 (D. Del.) |
Dec. 23, 2016 |
Hon. Sue L. Robinson |
Suboxone® (buprenorphine / naloxone sublingual film) |
9,370,512 |
| Sanofi-Aventis U.S. LLC v. Accord Healthcare, Inc., 16-1311 (D. Del.) |
Dec. 27, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Sanofi-Aventis U.S. LLC v. Apotex, Inc., 16-1312 (D. Del.) |
Dec. 27, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Sanofi-Aventis U.S. LLC v. Alembic Pharms. Ltd., 16-1316 (D. Del.) |
Dec. 28, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Sanofi-Aventis U.S. LLC v. Glenmark Pharms. Inc., USA, 16-1326 (D. Del.) |
Dec. 29, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| AstraZeneca AB v. Cipla Ltd., 16-9583 (D.N.J.) |
Dec. 29, 2016 |
Hon. Mary L. Cooper |
Nexium® 24HR (esomeprazole magnesium delayed-release capsules) |
6,369,085, 7,411,070 |
| Sanofi-Aventis U.S. LLC v. Emcure Pharms. Ltd., 16-1330 (D. Del.) |
Dec. 30, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
9,186,346 |
| Sanofi-Aventis U.S. LLC v. Torrent Pharma Inc., 16-1333 (D. Del.) |
Dec. 30, 2016 |
Hon. Gregory M. Sleet |
Aubagio® (teriflunomide tablets) |
6,794,410, 9,186,346 |
| Otsuka Pharm. Co., Ltd. v. Orchid Pharma Ltd., 16-9603 (D.N.J.) |
Dec. 30, 2016 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
9,358,207 |
Counsel
